--- title: "Q/C Technologies (QCLS) news: going concern and offering" url: "https://aibio.space/companies/q-c-technologies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "QCLS going concern, offering and Nasdaq notice news: Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report." --- QCLS Q/C Technologies, Inc. NASDAQ · United States # Q/C Technologies (QCLS) news QCLS going concern, offering and Nasdaq notice news Distress · 2025-11-14 ## [Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report](https://aibio.space/news/q-c-technologies-files-nt-10-q-late-filing-notice-september-2025/) Q/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning. ## Latest Q/C Technologies news 1. 2025-09-26 Financings [Q/C Technologies, formerly TNF Pharmaceuticals, starts trading as QCLS](https://aibio.space/news/q-c-technologies-formerly-tnf-pharmaceuticals-starts-trading-qcls/) The former TNF Pharmaceuticals began trading on Nasdaq as QCLS on September 26, 2025, under a new name tied to a licensed laser computing technology. The filing does not state how much the September private placement raised. 2. 2025-08-14 Distress [TNF Pharmaceuticals (now Q/C Technologies) delays June quarter report](https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-delays-june-quarter-report/) TNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers. 3. 2025-03-21 Listings [TNF Pharmaceuticals (now Q/C Technologies) gets Nasdaq minimum bid price notice](https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-gets-nasdaq-minimum-bid/) Nasdaq told TNF Pharmaceuticals on March 17, 2025 that its closing bid price was below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and remains listed on the Nasdaq Capital Market. 4. 2025-03-21 Listings [TNF Pharmaceuticals (now Q/C Technologies) gets Nasdaq minimum bid notice](https://aibio.space/news/tnf-pharmaceuticals-now-q-c-technologies-gets-nasdaq-minimum-bid/) TNF Pharmaceuticals, now Q/C Technologies, has until September 15, 2025 to bring its closing bid price back to $1.00 for ten business days. ## Q/C Technologies at a glance - **Ticker**: QCLS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $11.0 million ### Related companies - [RETRACTABLE TECHNOLOGIES INC](https://aibio.space/companies/retractable-technologies/) NYSE: RVP - [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) AMEX: APUS - [SpyGlass Pharma](https://aibio.space/companies/spyglass-pharma/) NASDAQ: SGP - [ICON](https://aibio.space/companies/icon/) NASDAQ: ICLR - [Frontage Holdings](https://aibio.space/companies/frontage/) HKEX: 1521 - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [IDEXX LABORATORIES INC /DE](https://aibio.space/companies/idexx-laboratories-de/) NASDAQ: IDXX - [MYOMO, INC.](https://aibio.space/companies/myomo/) NYSE: MYO ### Also on NASDAQ - [Envoy Medical](https://aibio.space/companies/envoy-medical/) COCH - [Novavax](https://aibio.space/companies/novavax/) NVAX - [MannKind](https://aibio.space/companies/mannkind/) MNKD - [InspireMD](https://aibio.space/companies/inspiremd/) NSPR - [Rhythm Pharmaceuticals](https://aibio.space/companies/rhythm-pharmaceuticals/) RYTM - [Pluri](https://aibio.space/companies/pluri/) PLUR ## Q/C Technologies annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | [$3.4 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | | Net income (loss) | [-$11.6 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | [-$23.4 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | | Cash from operations | [-$9.1 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | [-$9.0 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | | Cash and equivalents | [$986,996](https://www.sec.gov/Archives/edgar/data/1321834/000149315226037333/) | [$173,154](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | | Short-term investments | [$14.8 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226037333/) | [$8.3 million](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $307,612, plus short-term investments of $10.7 million, $11.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Q/C Technologies Has Q/C Technologies issued a going-concern warning? Our latest story on this, dated Nov 14, 2025: "Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/q-c-technologies-files-nt-10-q-late-filing-notice-september-2025/). Has Q/C Technologies raised money recently? Our latest story on this, dated Sep 26, 2025: "Q/C Technologies, formerly TNF Pharmaceuticals, starts trading as QCLS". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/q-c-technologies-formerly-tnf-pharmaceuticals-starts-trading-qcls/). Has Q/C Technologies received a Nasdaq deficiency notice? Our latest story on this, dated Nov 14, 2025: "Q/C Technologies files NT 10-Q late-filing notice for its September 2025 quarterly report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/q-c-technologies-files-nt-10-q-late-filing-notice-september-2025/). What is the ticker symbol of Q/C Technologies? Q/C Technologies, Inc. trades under the ticker QCLS on NASDAQ. Where is Q/C Technologies listed? Q/C Technologies, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0A8D. What is the SEC CIK of Q/C Technologies? The SEC Central Index Key (CIK) for Q/C Technologies, Inc. is 1321834. Its filings are on SEC EDGAR. How many shares does Q/C Technologies have outstanding? 8,189,838 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Q/C Technologies listed under? Our directory records Q/C Technologies, Inc. under United States. What does Q/C Technologies do? Our directory classifies Q/C Technologies, Inc. as: Mixed biopharma / computing infrastructure. This is a directory classification, not a description of the pipeline. What is the ISIN of Q/C Technologies? The ISIN recorded for Q/C Technologies, Inc. is US62856X3008. Does aibio.space cover Q/C Technologies? aibio.space lists Q/C Technologies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Q/C Technologies incorporated? SEC records list its state or country of incorporation as DE. Is Q/C Technologies profitable? Q/C Technologies, Inc. reported a net loss of $11.6 million for the fiscal year ended Dec 31, 2025, and used $9.1 million of cash in operations, per its annual report to the SEC. How much does Q/C Technologies spend on research and development? $3.5 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Q/C Technologies have? $11.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Q/C Technologies Members talk about Q/C Technologies (QCLS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Q/C Technologies, newest first. Each line links the filing it comes from. 1. 2026-09-11 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315226042394/form8-k.htm) 2. 2026-07-02 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315226031946/form8-k.htm) 3. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315226014222/formnt10-k.htm) 4. 2026-03-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315226010070/form8-k.htm) 5. 2025-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315225023598/formnt10-q.htm) 6. 2025-10-20 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315225018665/formdef14a.htm) 7. 2025-10-10 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315225017816/formpre14a.htm) 8. 2025-09-26 Financings Reported a financing. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315225015774/ex99-1.htm) 9. 2025-09-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,3.02,3.03,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225026167/ex99-1.htm) 10. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225024152/formnt10-q.htm) 11. 2025-06-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225014103/form8-k.htm) 12. 2025-04-21 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225005592/formdef14a.htm) 13. 2025-04-11 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225003814/form10-k.htm) 14. 2025-04-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225003848/formpre14a.htm) 15. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1321834/000164117225001852/formnt10-k.htm) 16. 2025-03-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1321834/000149315225011160/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:QCLS on TradingView](https://www.tradingview.com/symbols/NASDAQ-QCLS/). ## SEC filings and registration - **SEC name**: Q/C Technologies, Inc. - **CIK**: 1321834 - **Industry (SIC)**: In Vitro & In Vivo Diagnostic Substances (2835) - **US tickers**: QCLS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036 - **Phone**: 856-848-8698 - **Shares outstanding**: 8,189,838 as of 2026-08-12 (10-Q filed 2026-08-12) - **Former names**: Q/C TECHNOLOGIES, INC.; TNF Pharmaceuticals, Inc.; MyMD Pharmaceuticals, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1321834/000149315226043401/form8-k.htm) filed 2026-09-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1321834/000149315226042394/form8-k.htm) filed 2026-09-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1321834/000149315226037333/form10-q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1321834/000149315226031946/form8-k.htm) filed 2026-07-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1321834/000149315226023751/form10-q.htm) filed 2026-05-15 - [10-K](https://www.sec.gov/Archives/edgar/data/1321834/000149315226016872/form10-k.htm) filed 2026-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1321834/000149315226010070/form8-k.htm) filed 2026-03-13 - [S-3](https://www.sec.gov/Archives/edgar/data/1321834/000149315226006234/forms-3.htm) filed 2026-02-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001321834), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Q/C Technologies, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker QCLS, recorded under United States. The directory classifies it as Mixed biopharma / computing infrastructure. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Q/C Technologies, Inc. - **Ticker**: QCLS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Mixed biopharma / computing infrastructure - **ISIN**: US62856X3008 - **Other listed symbols**: LSE:0A8D - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-QCLS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/q-c-technologies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Q/C Technologies (QCLS) news: going concern and offering", 2026-10-31, https://aibio.space/companies/q-c-technologies/